Shadow AI & Billion-Dollar Oncology Bets: The State of Enterprise Risk
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
Summary
This episode maps the full shape of that risk — the difference between visibility and control, the attribution problem that makes incident response harder, and the organisational design challenge of retrofitting governance onto tools employees are already deeply embedded in.
The contrast comes from healthcare. Xaira Therapeutics has closed a one-billion-dollar funding round. A Sanofi and Insilico Medicine deal has reached one-point-two billion dollars. Both target AI-driven lung cancer therapeutics, where AI is now achieving between eighty-five and ninety-five percent accuracy in biomarker identification — a figure that changes what precision oncology can actually deliver. AI platforms are also compressing clinical trial timelines by optimising patient recruitment and running drug formulation in parallel.
The episode holds both signals together: enterprises losing control of AI already inside their walls, and a healthcare sector building AI into the architecture of drug discovery from day one. The gap between those two approaches is one of the clearest reads on where AI risk and AI opportunity are actually diverging right now.
This episode includes AI-generated content. A YesOui.ai Production.
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_c
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.